Pay in 4 interest-free payments of $6.06 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
BW: Writing original draft
CrossRef Tirzepatide and metabolic dysfunction-associated steatotic liver disease (MASLD) in obesity: a real-world multicenter study Martina Galasso, Ludovica Verde, Renato Patrone, Giovanni Ragozzino, Giuseppe Annunziata, Annamaria Colao, Luigi Barrea, Giovanna Muscogiuri Frontiers in Endocrinology.2026;[Epub] CrossRef Association of fat-related metabolic indices with MASLD and liver fibrosis: a cross-sectional analysis of NHANES 20172020 Neng Shen, Qinghua Wei, Jiangang Zhao, Jiacheng Cai Medicine.2026
In one small clinical trial that looked at treating nonalcoholic fatty liver disease, participants who took berberine every day for three months experienced significant weight loss
For biohackers, its a peptide worth watching, but with an informed eye on risk, variability, and lack of regulatory oversight
The semaglutide prescribing information (Ozempic, US label) carries a warning for acute pancreatitis, including fatal and non-fatal haemorrhagic or necrotising cases
Science 361 , 6408 (2018)
US$ 20.23
US$ 24.31
US$ 22.15
US$ 22.69
US$ 21.13
